Copyright © 2016
Aridis Pharmaceuticals, Inc.
5941 Optical Court, San Jose, CA 95138
Acute Pneumonia from Infections Acquired in Hospitals – An Increasing Problem
Infections acquired in hospitals and nursing homes, such as hospital-
Patients with compromised immune systems, including the elderly and very young, are especially susceptible. Hospital-
Patients in the Intensive Care Unit (ICU) contract hospital-
Current and Future Treatment of Hospital-
As a consequence, the risk of death from a serious infection in an ICU setting has been estimated to be as high as 50%. In addition, the resulting prolonged ICU/hospital stay and additional medication and intensive care interventions can dramatically increase hospitalization costs. Thus, there is not only a very high medical need, but also an economic need for new anti-
Combining mAb treatment with antibiotics can lead to more rapid resolution of infection, resulting in shorter stays in ICU and a significant reduction of morbidity, mortality and health care costs.
Antibodies are the workhorses of the human immune response, targeting and eliminating invading pathogens. The advantages to using therapeutic monoclonal antibodies, in addition to current therapy, are several fold:
The concept of combining monoclonal antibodies with standard-
With its fully human therapeutic antibodies, Aridis is well positioned to be a leader in this field.
P. Aeruginosa Virus
Staphylococcus aureus Bacteria
Breakthrough Therapies for
Antibiotic Resistant Infections